Allergy Therapeutics presents findings at EAACI

Allergy Therapeutics PLC

13 June 2025

 

Allergy Therapeutics plc

("Allergy Therapeutics", or the "Group")

Allergy Therapeutics presents key scientific findings from research portfolio at EAACI 2025

13 June 2025: Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, today announces that it will share key scientific findings from across its research portfolio at the European Academy of Allergy and Clinical Immunology (EAACI) Congress, taking place from today until 16 June in Glasgow, United Kingdom.

The EAACI Congress is the world's largest scientific conference specialising in the field of allergy and clinical immunology and the flagship meeting of the European Academy of Allergy and Clinical Immunology. The Academy is an association of more than 16,000 clinicians, researchers and allied health professionals from 124 countries, dedicated to improving the health of people affected by allergic diseases.

Among its posters being presented, Allergy Therapeutics will share:

• Preliminary clinical proof of concept for the Group's novel immunomodulating peanut allergy vaccine candidate demonstrated in peanut-allergic patients after three injection days, four weeks apart at two low cumulative doses. The peanut allergy vaccine candidate, currently at the final cohort stage of the first-in-human Phase I/IIa PROTECT trial, shows a benign safety profile in healthy subjects and peanut allergic patients. Moreover, it has demonstrated a strong dose-dependent reduction in skin-prick-test wheal size at low cumulative doses, accompanied by concordant biomarker changes supporting its hypoallergic mode of action in combination with early signs of a potent, clinically meaningful immune response.
• ​Data showing a statistically significant, clinically relevant and consistent improvement in Rhinoconjunctivitis Quality of Life Questionnaire score and for all corresponding quality of life subdomains in patients with allergic rhinitis and/or rhinoconjunctivitis treated with Grass MATA MPL, the Group's short-course subcutaneous immunotherapy candidate, compared with two registered grass sublingual immunotherapy products.
• Biomarker findings from the pivotal Phase III G306 trial demonstrating that Grass MATA MPL induces a tolerogenic immune signature, including elevated grass-specific IgG₄ and IgA, the induction of functional blocking antibodies, strong reduction of the allergic response pathway by suppressing basophil activity and a shift in T-cell populations from Th2 to Th1 and regulatory T cells, in grass-allergic patients.

Furthermore, Allergy Therapeutics will host a symposium on Friday, 13 June, 16:30-17:30 BST, chaired by Dr. Montserrat Alvaro, Paediatric Allergist, Paediatric Allergology and Clinical Immunology Department, Hospital Sant Joan de Déu, Barcelona, Spain. The symposium will feature expert perspectives on the evolving treatment landscape for peanut allergy, including clinical and regulatory considerations, and a deeper dive into the results of the Group's PROTECT trial, in addition to an overview of its short course Grass MATA MPL immunotherapy designed to address the symptoms of grass allergy.

"We are excited to engage with the global allergy and immunology community at EAACI 2025, sharing the latest advancements from our pipeline," said Manuel Llobet, Chief Executive Officer of Allergy Therapeutics. "The preliminary clinical proof of concept for our peanut allergy vaccine candidate and the positive quality of life findings from our Grass MATA MPL programme highlight the potential of our pipeline to transform patient care. These developments provide strong confidence in the potential for expansion of our VLP platform in food allergy and beyond, and reflect our dedication to delivering effective, short-course treatments that address the underlying causes of allergic disease and, ultimately, transform patients' lives."

The full list of Allergy Therapeutics-sponsored abstracts accepted for presentation is available on the Group's website.

No new material price-sensitive information is expected to be disclosed at the EAACI Congress.

Allergy Therapeutics' Symposium Friday, 13 June; 16:30-17:30 (BST)
Introduction Chair: Dr. Montserrat Alvaro, Paediatric Allergist, Paediatri Allergology and Clinical Immunology Department, Hospital Sant Joan de Déu, Barcelona, Spain	Our commitment to patients
Speaker Professor Lawrence DuBuske, Clinical Professor Medicine, George Washing University School of Medicine, Washington, DC, United States	State-ot-the-art evidence
Speaker Dr. Wayne Shreffler, Division Chief, Pediatric Allergy and Immunology, Mass General Hospital for Children, Boston, United States	Changes in the peanut allergy treatment paradigm
All Speakers	Q&A session

- ENDS -

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

[phone]

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash / Giles Balleny / Seamus Fricker

Nigel Birks - Life Science Specialist Sales

Tamar Cranford Smith - Sales

[phone]

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

[phone]

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapies that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. For more information, please see www.allergytherapeutics.com.

 

END